Efficacy of bezlotoxumab to prevent recurrent Clostridioides difficile infection (CDI) in patients with multiple prior recurrent CDI.

Autor: Skinner AM; Loyola University Medical Center, Department of Medicine, Maywood, IL, USA; Edward Hines Jr., Veteran Affairs Hospital, Research Section, Infection Diseases Section, Hines, IL, USA. Electronic address: Andrew.Skinner@va.gov., Tan X; University of Illinois at Chicago, College of Pharmacy, Chicago, IL, USA. Electronic address: xingtan70@gmail.com., Westman C; Spectrum Health Lakeland, Department of Medicine, Saint Joseph, MI, USA; Michigan State University College of Osteopathic Medicine, Department of Medicine, East Lansing, MI, USA. Electronic address: westcman@sbcglobal.net., Birris T; Spectrum Health Lakeland, Department of Medicine, Saint Joseph, MI, USA; Michigan State University College of Osteopathic Medicine, Department of Medicine, East Lansing, MI, USA. Electronic address: trbirris@gmail.com., Drwiega EN; University of Illinois at Chicago, College of Pharmacy, Chicago, IL, USA. Electronic address: edrwiega@uic.edu., Wang MS; Spectrum Health Lakeland, Department of Medicine, Saint Joseph, MI, USA; Michigan State University College of Osteopathic Medicine, Department of Medicine, East Lansing, MI, USA. Electronic address: Michael.Wang@corewellhealth.org., Johnson S; Loyola University Medical Center, Department of Medicine, Maywood, IL, USA; Edward Hines Jr., Veteran Affairs Hospital, Research Section, Infection Diseases Section, Hines, IL, USA. Electronic address: stuart.johnson2@va.gov.
Jazyk: angličtina
Zdroj: Anaerobe [Anaerobe] 2023 Dec; Vol. 84, pp. 102788. Date of Electronic Publication: 2023 Nov 04.
DOI: 10.1016/j.anaerobe.2023.102788
Abstrakt: Among 23 patients with multiply recurrent Clostridioides difficile infection (mrCDI) who received bezlotoxumab at the end of antibiotic treatment a sustained clinical response of 91 % at 30 days and 78 % at 90 days was achieved. Bezlotoxumab administered at the end of antibiotic treatment was effective in patients with mrCDI.
Competing Interests: Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.
(Published by Elsevier Ltd.)
Databáze: MEDLINE
Externí odkaz: